Brought to you by 
Replidyne closes $40mm second round
26 Oct 2012
Executive Summary
Anti-infectives developer Replidyne raised $40mm from its second round of venture financing. New investors TPG Ventures (an affiliate of the Texas Pacific Group), led the round and Perseus-Soros Biopharmaceutical Fund purchased significant amounts of equity. Returning investors HealthCare Ventures, Morgenthaler Ventures, and Sequel Venture Partners also participated.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Replidyne closes $40mm second round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice